Scarica l'app Stockscreener
74.17
1.98%
1.44
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$72.73
Aprire:
$73.17
Volume 24 ore:
887.72K
Relative Volume:
1.01
Capitalizzazione di mercato:
$3.37B
Reddito:
$1.33B
Utile/perdita netta:
$97.31M
Rapporto P/E:
36.51
EPS:
2.0317
Flusso di cassa netto:
$260.44M
1 W Prestazione:
-7.10%
1M Prestazione:
+29.49%
6M Prestazione:
-7.17%
1 anno Prestazione:
+5.87%
Intervallo 1D:
$72.29
$74.53
Intervallo di 1 settimana:
$72.29
$80.94
Portata 52W:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Nome
Haemonetics Corp
Settore
Industria
Telefono
(781) 848-7100
Indirizzo
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
74.17 | 3.37B | 1.33B | 97.31M | 260.44M | 2.0317 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-15 | Downgrade | Needham | Buy → Hold |
| 2025-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2025-08-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Reiterato | Barrington Research | Outperform |
| 2025-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-06-26 | Iniziato | Robert W. Baird | Outperform |
| 2025-02-07 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Iniziato | JP Morgan | Overweight |
| 2024-11-08 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Iniziato | CL King | Buy |
| 2024-09-11 | Iniziato | BofA Securities | Neutral |
| 2024-09-10 | Iniziato | BTIG Research | Buy |
| 2024-06-12 | Aggiornamento | Needham | Hold → Buy |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2022-01-27 | Downgrade | Needham | Buy → Hold |
| 2021-12-15 | Downgrade | Citigroup | Buy → Neutral |
| 2021-08-17 | Ripresa | Raymond James | Outperform |
| 2021-06-17 | Iniziato | Citigroup | Buy |
| 2021-05-14 | Aggiornamento | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Aggiornamento | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Iniziato | Needham | Buy |
| 2019-08-07 | Reiterato | Barrington Research | Outperform |
| 2019-05-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Reiterato | Barrington Research | Outperform |
| 2018-08-09 | Reiterato | Barrington Research | Outperform |
| 2018-02-07 | Reiterato | Barrington Research | Outperform |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Reiterato | Barrington Research | Outperform |
| 2017-08-08 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Reiterato | The Benchmark Company | Hold |
| 2016-09-20 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Downgrade | Sidoti | Buy → Neutral |
| 2016-08-02 | Reiterato | Jefferies | Buy |
| 2016-08-02 | Reiterato | The Benchmark Company | Hold |
Mostra tutto
Haemonetics Corp Borsa (HAE) Ultime notizie
Quietly ambitious, Haemonetics NexSys PCS pushes plasma efficiency further - AD HOC NEWS
Why Haemonetics’ NexSys PCS quietly reshapes plasma collection on the clinic floor - AD HOC NEWS
Haemonetics Corp (HAE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Haemonetics Corp (HAE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Haemonetics Corp (HAE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Haemonetics Corp (HAE) Institutional Confidence - TradingKey
Haemonetics Corp (HAE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Haemonetics Corp (HAE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Haemonetics Corp (HAE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Haemonetics Corp (HAE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Loomis Sayles Small Cap Core Portfolio's Haemonetics Corp(HAE) Holding History - GuruFocus
HAE Reiterated by BTIG -- Price Target Maintained at $84.00 - GuruFocus
Haemonetics Corp (HAE) Shares Fall 3.2% -- What GF Score of 77 T - GuruFocus
HAE Maintained by Mizuho -- Price Target Raised to $85.00 - GuruFocus
Mizuho raises Haemonetics stock price target to $85 on plasma demand - Investing.com UK
Mizuho Securities Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $85 - 富途牛牛
Haemonetics Corp (HAE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HAE SEC FilingsHaemonetics Corp Mass 10-K, 10-Q, 8-K Forms - Stock Titan
Is Haemonetics’ (HAE) Apheresis Reorg Quietly Redefining Its Competitive Edge in Medical Devices? - simplywall.st
HAEMONETICS CORP ($HAE) President and CEO 2026 Pay Revealed - Quiver Quantitative
[ARS] HAEMONETICS CORP SEC Filing - Stock Titan
Executive pay and equity plans in Haemonetics (NYSE: HAE) 2026 proxy filing - Stock Titan
A Look At Haemonetics (HAE) Valuation After Its New Apheresis And MedSurg Segment Realignment - Yahoo Finance
A Look at Haemonetics Corp (HAE) After 5.0% Gain -- GF Value $84 - GuruFocus
Haemonetics (NYSE: HAE) VP settles RSU taxes with 259 withheld shares - Stock Titan
Haemonetics (HAE) SVP has 313 shares withheld for RSU tax obligations - Stock Titan
Haemonetics Corp at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Haemonetics Corp stock (US4041191090): solid growth story in blood management and plasma technology - AD HOC NEWS
Is Haemonetics (HAE) Stock Price Reflecting Its Recent 29% Monthly Surge Accurately - simplywall.st
Haemonetics Corp stock (US4041191090): segment restructuring shifts focus to Apheresis and MedSurg - AD HOC NEWS
Haemonetics Restructures Business Segments for Enhanced Efficien - GuruFocus
Haemonetics Updates Financial Reporting Segments, Combines Plasma and Blood Center Into Apheresis, Renames Hospital to MedSurg 1 - Minichart
Haemonetics restructures reporting segments from three to two - Investing.com
Haemonetics updates reporting structure, combines Plasma and Blood Center into Apheresis - TradingView
Haemonetics (NYSE: HAE) consolidates business into new Apheresis and MedSurg segments - Stock Titan
Haemonetics Updates Financial Reporting Segments - PR Newswire
Haemonetics Corp (HAE) Shares Surge 6.0% -- What GF Score of 79 Tells Investors - GuruFocus
Haemonetics earnings ahead: Can vascular closure rebound? - Investing.com
Haemonetics stock falls from recent highs amid weekly seller pressure and overbought signals - Traders Union
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference - PR Newswire
Haemonetics Corp stock (US4041191090): shares trade lower after recent pullback on NYSE - AD HOC NEWS
HAE Maintained by Citigroup -- Price Target Raised to $70 - GuruFocus
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Raises Target Price to $70 - 富途牛牛
Why Haemonetics NYSE Composite Earnings Sparked Attention? - Kalkine Media
Haemonetics' (NYSE:HAE) Conservative Accounting Might Explain Soft Earnings - simplywall.st
Why Haemonetics (HAE) Is Up 14.3% After Earnings Beat And BofA Upgrade And What's Next - Yahoo Finance
Is It Time To Reassess Haemonetics (HAE) After The Recent Share Price Jump - simplywall.st
Haemonetics (HAE) Stock Is Up, What You Need To Know - Yahoo Finance
Medical Devices & SuppliesSpecialty Stocks Q1 Highlights: Haemonetics (NYSE:HAE) - Yahoo Finance
Haemonetics (HAE) Upgraded to Buy by Bank of America, Target Pri - GuruFocus
HAE Upgraded by B of A Securities -- Price Target Raised to $80 - GuruFocus
Haemonetics Corp Azioni (HAE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):